Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Ophthalmology"
DOI: 10.1001/jamaophthalmol.2017.6565
Abstract: Importance Prevalence of persistent central-involved diabetic macular edema (DME) through 24 weeks of anti–vascular endothelial growth factor therapy and its longer-term outcomes may be relevant to treatment. Objective To assess outcomes of DME persisting at… read more here.
Keywords: bevacizumab ranibizumab; bevacizumab; persistent dme; aflibercept bevacizumab ... See more keywords